![Kathryn Haviland](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathryn Haviland
Chairman at
FULCRUM THERAPEUTICS, INC.
Net worth: 161 755 $ as of 2026-05-30
Profile
Kathryn Haviland is on the board of Fulcrum Therapeutics, Inc. and Chief Operating Officer at Blueprint Medicines Corp., Member of Harvard Business School Health Industry Alumni Association and Member of Biopharma Executive Council. Ms. Haviland previously occupied the position of Vice President-Rare Diseases at Idera Pharmaceuticals, Inc., Head-Commercial Development at Sarepta Therapeutics, Inc. and Executive Director-Commercial Development at PTC Therapeutics, Inc. She received an undergraduate degree from Wesleyan University and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-08 | 7,437 ( 0.01% ) | 161 755 $ | 2026-05-30 | |
| 2026-03-30 | 0 ( -.--% ) | - $ | 2026-05-30 | |
AVALYN PHARMA INC -.--% | 2026-04-29 | 0 ( -.--% ) | - $ | 2026-05-30 |
Kathryn Haviland active positions
| Companies | Position | Start |
|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Chairman | 2022-01-09 |
| BICARA THERAPEUTICS INC. | Director/Board Member | 2023-09-20 |
| AVALYN PHARMA INC. | Director/Board Member | 2026-02-28 |
Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Corporate Officer/Principal | - |
Former positions of Kathryn Haviland
| Companies | Position | End |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Executive Officer | 2025-12-31 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Corporate Officer/Principal | 2015-11-30 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 2014-03-31 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 2012-05-31 |
Training of Kathryn Haviland
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
74
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Wesleyan University
 Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Harvard Business School Health Industry Alumni Association | |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulcrum Therapeutics, Inc.
 Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Operates as biotech and pharmaceutical executive level membership council | Commercial Services |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
- Stock Market
- Insiders
- Kathryn Haviland
